These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34908007)

  • 1. Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).
    Sebastian M; Gröschel A; Gütz S; Schulz H; Müller-Huesmann H; Liersch R; von der Heyde E; Wiegand J; Ukena D; Bargon J; Schütte W; Riera-Knorrenschild J; Fischer JR; Griesinger F; Allan V; Waldenberger D; Schumann C
    J Immunother; 2022 Feb-Mar 01; 45(2):89-99. PubMed ID: 34908007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
    Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
    Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
    Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
    ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.
    Lim SM; Kim SW; Cho BC; Kang JH; Ahn MJ; Kim DW; Kim YC; Lee JS; Lee JS; Lee SY; Park KU; An HJ; Cho EK; Jang TW; Kim BS; Kim JH; Lee SS; Na II; Yoo SS; Lee KH
    Cancer Res Treat; 2020 Oct; 52(4):1112-1119. PubMed ID: 32599984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
    Juarez-Garcia A; Sharma R; Hunger M; Kayaniyil S; Penrod JR; Chouaïd C
    Lung Cancer; 2022 Apr; 166():205-220. PubMed ID: 35316754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.
    Barlesi F; Dixmier A; Debieuvre D; Raspaud C; Auliac JB; Benoit N; Bombaron P; Moro-Sibilot D; Audigier-Valette C; Asselain B; Egenod T; Rabeau A; Fayette J; Sanchez ML; Labourey JL; Westeel V; Lamoureux P; Cotte FE; Allan V; Daumont M; Dumanoir J; Reynaud D; Calvet CY; Ozan N; Pérol M
    Oncoimmunology; 2020 Apr; 9(1):1744898. PubMed ID: 33457089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.
    Areses Manrique MC; Mosquera Martínez J; García González J; Afonso Afonso FJ; Lázaro Quintela M; Fernández Núñez N; Azpitarte Raposeiras C; Amenedo Gancedo M; Santomé Couto L; García Campelo MR; Muñoz Iglesias J; Cortegoso Mosquera A; Vilchez Simo R; Casal Rubio J; Campos Balea B; Carou Frieiro I; Alonso-Jaudenes Curbera G; Anido Herranz U; García Mata J; Fírvida Pérez JL
    Transl Lung Cancer Res; 2018 Jun; 7(3):404-415. PubMed ID: 30050778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
    Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
    J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
    Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
    Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
    Wolf A; Stratmann JA; Shaid S; Niklas N; Calleja A; Ubhi H; Munro R; Waldenberger D; Carroll R; Daumont MJ; Penrod JR; Lacoin L; Rohde G
    BMC Pulm Med; 2023 Jan; 23(1):16. PubMed ID: 36639770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
    Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
    J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.